公开(公告)号：US20190282541A1

公开(公告)日：2019-09-19

申请号：US16318198

申请日：2017-07-20

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Bruce A. LITTLEFIELD ,  Gary HENDLER

IPC: A61K31/357 ,  A61K31/4406 ,  A61K31/565 ,  A61P35/04

Abstract: The invention features methods for treating and preventing cancer (e.g., a hormone sensitive cancer) in a patient in need thereof by administering eribulin (e.g., eribulin mesylate) in combination with a histone deacetylase (HDAC) inhibitor.

公开(公告)号：US20170100367A1

公开(公告)日：2017-04-13

申请号：US15314160

申请日：2015-05-27

Applicant: Bruce A. Littlefield ,  Eisai R&D Management Co., Ltd.

Inventor： Makoto ASANO ,  Bruce A. LITTLEFIELD ,  Junji MATSUI ,  Martin OLIVO ,  Yoichi OZAWA ,  Yanke YU

IPC: A61K31/357 ,  A61K31/7068 ,  A61K31/282 ,  A61K31/704 ,  A61K31/427 ,  A61K9/00 ,  A61K31/337

Abstract: The invention features methods and kits for use in treating cancer in a patient in need thereof by administering eribulin or a pharmaceutically-acceptable salt thereof (e.g., eribulin mesylate) prior to a second agent.